Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

This article was retracted on 23 December 2023

This article has been updated

Abstract.

Objective: The purpose of this study was to examine the effects of of bromocriptin combined with clomiphene citrate in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Design: Prospective, double-blind, controlled study. Setting: University teaching hospital. Patients: One hundred polycystic ovary patients and normal prolactin (PRL) who were clomiphene citrate resistant. Interventions: Treatment group received 150 mg clomiphene citrate on days 5–9 and 7.5 mg bromocriptin continuously. Control group received the same protocol of clomiphene citrate combined with placebo. Main outcome measures: Hormonal status, follicular monitoring, ovulation rate. Results: Follicular development (follicular size greater than 15 mm) was observed in 12 (25.5%) and eight (15.1%) women in treatment and placebo group respectively (P=0.29). The serum prolactin level was within normal limits in all patients before treatment. After 3 and 6 months of treatment with bromocriptin, there was a significant decrease in serum level of prolactin (P=0.000001).No any significant differences was seen in ovulation, and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), progesterone (P) between treatment and placebo group after treatment. Conclusions: The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration. It was also concluded that 10–15% of patients with polycystic ovaries experienced occasional ovulatory cycles and pregnancy whether or not they were on treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. Branigan EF, Estes MA (1999) Treatment of chronic anovulation resistant to clomiphene citrate(CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment. Fertil Steril 71:544–546

    Article  PubMed  CAS  Google Scholar 

  2. Buvat J,Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Beuscart R, Fossati P (1986) A double blind controlled study of the hormonal and clinical effects of bromocriptin in the polycystic ovary syndrome. Clin Endocrinol Metab 63:119–124

    Article  CAS  Google Scholar 

  3. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Janni A (1984) Polycystic secretion in polycystic ovary syndrome: Correlation with the steroid pattern. Acta Endocrinol 105:99–104

    CAS  Google Scholar 

  4. Chapman AJ, Wilson MD, Obhari M, Sawers RS, Lynch SS, Royston JP, Clayton RN (1987) Effects of bromocriptin on LH pulsatility in the polycystic ovary syndrome. Clin Endocrinol 27:571–580

    Article  CAS  Google Scholar 

  5. Corenblum B, Taylor PJ (1980) A rational for the use of bromocriptin in patients with amenorrhea and normoprolactinemia. Fertil Steril 34:239–241

    Article  PubMed  CAS  Google Scholar 

  6. Ergur A (1998) Clomiphene citrate resistant polycystic ovary syndrome. J Reprod Med 43:185–190

    PubMed  CAS  Google Scholar 

  7. Falashi P, Del Pozo E (1986) Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 62:348–351

    Article  Google Scholar 

  8. Falashi P, Del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese J (1980) Prolactin release in polycystic ovary. Obstet Gynecol 55:579–582

    Google Scholar 

  9. Futterweit W, Krieger DT (1979) Pituitary tumors associated with hyperprolactinemia and polycystic ovarian disease. Fertil Steril 31:608–613

    Article  PubMed  CAS  Google Scholar 

  10. Kaptien EM, Kletzky DA, Spencer CA, Noolof JT (1980) Effects of prolonged dopamine infusion on anterior pituitary function. JCE & M 43:488–491

    Google Scholar 

  11. Kubota T, Kamada S, Aso T (1992) Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Int J Fertil 37:277–282

    PubMed  CAS  Google Scholar 

  12. Lunde O (1981) Hyperprolactinemia in polycystic ovary syndrome. Ann Chir Gynaecol 70:197–201

    PubMed  CAS  Google Scholar 

  13. Marco C (1998) Effects of clomiphene citrate on androgens in polycystic ovary syndrome. Archiv Gynecol Obestet 261:117–120

    Google Scholar 

  14. Mitwally FM, Casper RF (2001) Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75:350–359

    Article  Google Scholar 

  15. Peilon F, Vincens M, Ceselin F, Doumit R, Mouszowics I (1982) Exaggerated prolactin response to thyrotropin-releasing hormone in women with anovulatory cycles: Possible role of endogenous estrogens and effect of bromocriptine. Fertil Steril 37:530–535

    Article  Google Scholar 

  16. Prelevic GM, Wurzburger MI, Peric LA (1987) Acute effects of L-dopa and bromocriptin on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. J Endocrinol Invest 10:389–395

    Article  PubMed  CAS  Google Scholar 

  17. Rosato P, Minto F, Garrone S, Ragni N (2000) Growth hormone response to clomiphene in anovulatory infertile women resistant to clomiphne citrate stimulation. Fertil Steril 73:78–84

    Article  Google Scholar 

  18. Siginami H, Hamada K, Yano K, Kuroda G (1986) Ovulation induction with bromocriptin in noroprolactinemic anovulatory women. JCE & M 62:899–903

  19. Speroff L, Glass RH, Kase NG (1999) Anovulation and the polycystic ovary syndrome. Clinical gynecologic endocrinology and infertility, 6th edn. Williams and Wilkins, Baltimore, pp 487–521, 1105

  20. Spruce BA, Kenedal Taylor P, Donlope W, Anderson AJ, Watson MJ, cook DB et al (1984) The effect of bromocriptin in the polycystic ovary syndrome. Clin Endocrinol 20:481–488

  21. Steingold KA, Lobo RA, Judd HL, Lu JK, Chang RJ (1986) The effect of bromocriptin on gonadotropin and steroid secretion in polycystic ovarian disease. Clin Endocrinol Metab 62:1048–1051

    Article  CAS  Google Scholar 

  22. Takakura K, Taii S, Ihara Y, Takai I, Mori T (1989) Aggravation of inappropriate lutenizing hormone secretion by bromocriptin in polycystic ovary syndrome with elevated serum DEHAS. Endocrinol Jpn 36:261–268

    Article  PubMed  CAS  Google Scholar 

  23. Worstman J, Hirschowitz JS (1980) Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet Gynecol 55:460–463

    Google Scholar 

Download references

Acknowledgements.

We would like to gratefully acknowledge Professor Ernst Heinrich Schmidt, Chairman of the Obstetrics and Gynecology Department, Diako Hospital, Bremen Germany for his technical help and advices.

Author information

Author notes

  1. Mohammad Ebrahim Parsanezhad

    Present address: Jenaer Str 41, 28215, Bremen, Germany

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

    Mohammad Ebrahim Parsanezhad, Saeed Alborzi & Bahia Namavar Jahromi

Authors
  1. Mohammad Ebrahim Parsanezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Alborzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahia Namavar Jahromi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Ebrahim Parsanezhad.

Additional information

This work was performed at the Division of Infertility, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

About this article

Cite this article

Parsanezhad, M.E., Alborzi, S. & Namavar Jahromi, B. RETRACTED ARTICLE: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Arch Gynecol Obstet 269, 125–129 (2004). https://doi.org/10.1007/s00404-002-0437-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-002-0437-x

Keywords.

Search

Navigation